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IntroductIon 
In 2008 45% of pregnant women living with HIV and 
31% of infants born to women living with HIV received 
antiretroviral (ARV) drugs to prevent transmission of 
the virus from mother to child in sub-Saharan Africa 
(1). Although large gains in reaching HIV positive 
pregnant women with ARVs have been documented 
in the last few years, many countries still face major 
challenges. Of the 20 countries estimated to have the 
largest number of women needing ARVs to reduce 
perinatal HIV transmission, 12 countries currently 
reach less than 50% of the pregnant women estimated 
to need ARVs (1). 
	 Efficacy	of	the	ARV	used	to	prevent	perinatal	HIV	
transmission depends on the drug regimen. Single 
dose nevirapine offers about a 50% reduction in risk 
(2). Since 2006, countries have been shifting to more 
efficacious	regimens	with	combinations	of	two	or	three	
ARV drugs (1). Of pregnant women who tested HIV 
positive and received drugs in 2008, 31% received 
the single dose nevirapine regimen, while the rest 
received	ARVs	for	their	own	health,	more	efficacious	
regimens, or the regimen was “uncategorised”. 
 The World Health Organization (WHO) 
guidelines on the use of ARV drugs for treating 
pregnant women and preventing HIV infection in 
infants prioritise lifelong antiretroviral therapy (ART) 
to treat HIV in women (3). If women are not eligible 
for ART, then pre and peri-partum interventions 
should maximise the likelihood of reducing vertical 
HIV transmission and postpartum interventions 
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abstract 
Objective: to test whether a single take home dose of infant nevirapine increased 
infant uptake without decreasing institutional deliveries. 
Design: cluster randomized post-test only study with control group. 
Setting: ten hospitals in urban areas of coast, rift valley, and Western provinces, 
kenya. 
Participants: pregnant women with hIv, 18 years and older, and at least 32 weeks 
gestation recruited during antenatal care and followed up at home approximately 
one week after delivery. 
Intervention: In the intervention group, women were given a single infant’s dose of 
nevirapine to take home prior to delivery. In the control group, no changes were made 
to the standard of care. 
Main outcome measures: mothers’ reports of infant uptake of nevirapine and place 
of delivery. 
Results: uptake of the infant’s nevirapine dose was high, 94% in the intervention 
group and 88% in the control group (p=0.096). among women who delivered at home, 
uptake was higher significantly among infants whose mothers got the take home dose 
compared to women who did not get the dose (93% vs. 53%, p<0.01). the intervention 
did not influence place of delivery. Providers were positive about the take home dose 
concept; difficulties were attributed to HIV-related stigma. 
Conclusions: making take home infant nevirapine available, either as a single dose 
administered within 72 hours of birth or as part of a more complex six week postnatal 
regimen, will increase infant uptake especially among women who deliver at home 
without affecting place of delivery. 
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should facilitate safe breastfeeding. Although there 
has been a move away from single dose nevirapine 
for the mother’s regimen, the recommendations 
strengthen the role of nevirapine for the infant (3). 
daily administration of nevirapine to the infant is 
recommended from birth to six weeks for infants born 
to HIV-infected women receiving ART for their own 
health or until one week after all exposure to breastmilk 
for infants born to women not in need of ART. for 
nonbreastfeeding infants, the recommendations are 
nevirapine or zidovudine (AzT) until six weeks of 
age (3). 
 As a single dose regimen to mother and newborn, 
studies have demonstrated that nevirapine is an 
efficacious,	 low-cost,	 and	 practical	 prophylactic	
regimen for reducing mother-to-child transmission 
of HIV-1 in resource-limited settings (2,4). The single 
dose regimen includes a 200mg tablet of nevirapine 
taken by the mother at the onset of labour and a 
0.6ml dose of oral suspension nevirapine syrup for 
the infant within 72 hours of delivery (2). 
 In kenya in 2008, 56% of pregnant women 
living with HIV received ARVs for perinatal HIV 
prevention compared with 39% of their infants, and 
at the time of this study (2006) those proportions were 
slightly lower. Standard practice for administration of 
singledose nevirapine requires HIV positive women 
to deliver in health facilities or to return to the health 
facility within 72 hours after delivery so that the 
infant can get his/her dose of nevirapine. In many 
contexts, particularly rural locations, many births 
occur outside the health facility, which is the main 
barrier to uptake of the infant nevirapine dose (5). 
In kenya, the prevalence of home births is 29% for 
urban women and 66% for rural women (6). 
 Allowing women to take the infant’s nevirapine 
dose home from antenatal care (AnC), as is already 
done with the mother’s dose, could increase infant’s 
uptake. A study from Rakai, uganda demonstrated 
the “proof of concept” of the infant take home dose 
(7). However, this study relied on at-home HIV 
testing and counseling and nevirapine provision 
by midwives which may not be particularly cost-
effective, feasible, or even practiced outside of the 
Rakai context. packaging of the infant nevirapine 
dose is important, since the paediatric formulation 
is viscous in nature and the nevirapine must be 
distributed into syringe dispensers. nevirapine 
and the syringe dispenser are available at no-cost to 
participants of Boehringer Ingelheim (BI) donations 
program (Baxa Corporation, denver, CO) (8). 
 To improve the packaging of the infant’s 
nevirapine dose to facilitate taking it home, BI, the 
united States Agency for International development 
(uSAlb), and program for Appropriate Technology in 
Health (pATH) developed a self sealing foil pouch to 
protect	the	filled	Baxa	Exacta-Med	syringes	dispenser	
(9). The nevirapine infant dose pouch’s label provides 
pictorial instructions and expiry information (figure 
1). To help standardize the practice, pATH also 
developed a provider training manual (10). A pilot 
introduction of the pouch in kenya found high 
acceptability by both providers and mothers, and 
mothers thought the pouch was easy to use (11). The 
nevirapine infantdose pouch has recently been made 
available at no-cost as part of the BI prevention of 




1 ml Baxa Exacta-Med Dispenser filled to .06 ml and English label for the NVP infant-dose pouch
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 One of the concerns about implementing this 
intervention was its potential effect on current 
delivery practices. With the introduction of the 
syringe, nevirapine infant dose pouch, instructions 
and training material, we conducted a study to 
examine whether offering the infant dose to take home 
increases uptake without decreasing institutional 
deliveries As a secondary objective, this study 
assessed providers’ perspectives on the feasibility 
and acceptability of the take home dose. 
materIals and methods 
The study design was a cluster randomized post-
test only with control group (figure 2). Ten health 
facilities with high pmTCT client loads were matched 
on the following characteristics: province, type of 
facility, AnC client load, number of pmTCT trained 
providers, time since pmTCT implementation, and 
HIV testing uptake rate. pairs of facilities were 
randomly assigned to intervention or control group. 
facilities are all hospitals and are located in Coast, 
Rift Valley, and Western provinces of kenya. facilities 




 In-use stability studies conducted at BI suggest 
that the infant nevirapine dose should be used within 
two	months	after	filling	the	Baxa	Exacta-Med	syringe	
and putting it in the pouch (8), and this was the 
standard that was used in this study. In other words, 
to be eligible to receive the infant’s dose to take home 
and to participate in the study, women had to be at 
least 32 weeks gestation (with an assumed estimated 
date of delivery of approximately 40 weeks). 
 In the intervention facilities, pmTCT providers 
received training on how to repackage nevirapine 
syrup into the syringes, to seal the syringe with the 
pouch, to calculate the expiry date, and to counsel 
women on how to use the infant’s dose. Women in 
the intervention sites were given explicit instructions 
on how to store the repackaged nevirapine, to read 
the expiry dates, to open the foil, and to administer 
the drug. They were instructed that if they did not 
deliver in a health facility or were discharged before 
administration of nevirapine to the baby, they were to 
administer	nevirapine	to	the	baby	within	the	first	72	
hours. no changes were made in the administration 
of the woman’s nevi rapine dose; women still received 
their dose during AnC according to the national 
protocol. 
 In the control group, no changes were made to 
the standard of care. Women received their nevirapine 
dose during AnC as per the facility’s protocol and 
were counseled to deliver in the health facility or 
to return within 72 hours of delivery so that their 
newborns could receive their nevirapine dose. 
 In an effort to standardize the care across sites, 
providers in both the intervention and control groups 
used	a	flow	chart	job	aid	that	reviewed	the	process	
of how to offer optout HIV testing and post-HIV test 
counseling including key points to remember during 
counseling. The intervention facilities differed only in 
that	their	flow	chart	contained	information	on	how	
to offer the infant’s dose. Women in all the facilities 
were encouraged to deliver in health facilities. 
 Antenatal mothers aged 18 years and above 
who were HIV infected, had attained a gestation 
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of 32 weeks, and gave signed informed consent 
to participate were enrolled in the study. Women 
participated	 in	 two	 interviews.	The	first	 interview	
took place at the time of recruitment into the study 
after their AnC visit. This interview contained 
information about how to contact the mother for the 
follow up interview, her estimated date of delivery, 
socio-demographic information, pregnancy and 
contraceptive use history and intentions, use of health 
services, history of HIV testing, HIV status disclosure, 
knowledge of when to take nevirapine and reports 
of providers’ counseling on nevi rapine. 
 The second interview took place at the 
participant’s home (or another location at the 
participant’s suggestion) approximately one week 
after women delivered their infants. It investigated 
the factors associated with nevirapine administration, 
perspectives on administering nevirapine, HIV status 
disclosure, partners’ approval of nevirapine, health 
services use and intention, and infant’s nevirapine 
dose uptake. The details of nevirapine administration, 
including who administered it to the infant, where, 
and when, were based on mother’s reports during 
the second interview. 
 Interviews with providers sought their 
perspectives of the feasibility and acceptability of 
the practice. Interviews were conducted near the end 
of participant recruitment so that providers in the 
training group had enough time to gain experience 
dispensing the infant’s dose. 
 Sample size calculations determined that a 
sample of 190 women attending the 10 different 
facilities was needed to detect a 66% increase in 
uptake of the infant nevirapine dose (from 36% to 
60%). This sample size assumed 80% power, a false 
positive rate of 5% (one-tailed), a loss-to-follow up 
of 30%, and and intraclass correlation of 0.002. 
 The main outcome of the study, infant uptake 
of nevirapine, was measured based on mothers’ 
reports. Infant uptake of nevirapine was assessed 
by intervention or control group (intent-to-treat 
analysis) and by whether or not the mother received 
the take home dose. due to the small cluster size 
by design, the data are analysed as if no matching 
occurred as suggested by diehr et al. (12). Crude 
proportions of taking infant dose of nevirapine are 
calculated and compared by a 2x2 contingency table 
pearson chi-square test. Then, the difference in the 
estimated proportions are tested using a generalised 
estimating equation (Gee) methods with the identity 
link function and binomial variance (SAS version 
9.1.3). Only the Gee analyses account for clustering 
(at the facility level). We also analysed the bivariate 
relationship between maternal characteristics (age, 
education, employment, marital status, parity, 
number of AnC visits, and place of delivery) and 
infant uptake. All tests were conducted at the 0.05 
significant	level.	Tests	of	the	main	outcome	and	group	
are one-sided, while tests of characteristics and the 
main outcome are two-sided. finally, we conduct 
descriptive bivariable analyses (no statistical tests) of 
socio-demographic characteristics and reports of HIV 
testing, status disclosure, and partner perspectives 
stratified	by	group	to	help	with	the	interpretation	of	
the results. provider perspectives on the take home 
dose concept are also presented. 
 ethical approval to conduct this study was 
obtained from Institutional Review Boards of 
family Health International and kenyatta national 
Hospital. 
results 
The	 average	 time	 between	 the	 first	 and	 second	
interviews was 47 days in the intervention group 
(range 3-91 days) and 38 in the control group (range 
7-81 days). Intervals between interviews were shorter 
in the control group. This was because two of the 
five	 control	 facilities	 started	 data	 collection	 late	
necessitating recruitment of mothers nearer to date 
of delivery. 
 Babies were slightly older on average in the 
intervention group when the interviewer visited 
for the second interview than babies in the control 
group (15 days [range 0-65] vs. 8 days [range 1-20] 
on average). The average in the intervention group 
is	skewed	by	a	few	cases	that	were	difficult	to	follow	
up. We were able to verify with the data collection 
instruments (which were based on mothers’ reports) 
that all but one infant received their dose of nevirapine 
before the interviewer arrived to conduct the second 
interview. The one exception was where an infant in 
the intervention group received the nevirapine dose 
after the interviewer’s visit, so we conservatively 
treated that case as not having received the nevirapine 
dose in the analysis. Almost all of the infants were 
still alive at the time of the interview (99% in both 
groups). 
 One hundred and sixteen clients in the intervention 
group	and	87	in	the	control	group	agreed	to	the	first	
interview. Of these 85 clients in the intervention group 
(73%) and 75 (86%) in the control group participated in 
second interviews. We included all clients who agreed 
to	participate	in	the	first	interview	regardless	of	their	
willingness to participate in the second interview. many 
clients considered ‘lost-to-follow up’ had participated 
in	the	first	interview,	but	refused	to	participate	in	the	
second interview from the outset (19 of 31 clients in the 
intervention group and 4 of 12 in the control group). 
 Clients’ characteristics and health service 
use are presented in Table 1. Clients were in their 
mid 20’s with one to two children on average. The 
majority of clients had completed primary education 
and most were married. Two-thirds of clients were 
unemployed. About half of clients sought four or more 
AnC visits. few differences were noted between the 
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characteristics of those women in the intervention 
group compared to the control group. 
 There was no difference between intervention 
and control groups on place of delivery. The majority 
of women delivered in a health facility (Table 1). 
About one-third of clients in both groups delivered 
at home which is typical of kenyan women in urban 
areas (6). 
 uptake of the infant’s dose of nevirapine was 
high in both groups, 94% in the intervention group 
table 1
Socio-demographic characteristics and health service use of clients who completed the follow-up’ interview
 Intervention Group (n=85) Control Group (n=75) 
mean age (range)  27.4 (18-40)  28.4 (18-42) 
mean number of children (range) 1.6 (0-6) (%) 2.2 (0-9) (%)
education 
   none  16  19 
   primary (up to grade 7/8)  58  51 
   Secondary (up to form 4/6)  19  25 
   post-secondary/university  7  5 
marital status 
   married or living as married  81 81 
   Single  12 5 
   divorced/separated/widowed  7  13
employment status and income type  
   unemployed  76 76 
   Salaried/hourly1  7  9 
   Income based on sales or self-determined  15  15 
Total number of AnC visits made during this pregnancy 
   1  13  9 
   2  16  16
   3  22  21 
   4+ 47 53
place of delivery   
   Same health facility as recruited  44  44
   Respondent’s home /Another person’s home 38  37 
   Another health facility  16  16
   In transit to health facility  2  3 
1Only one woman reported income type of ‘hourly’ 
 
and 88% in the control group (p=0.096) (Table 2). 
However, some women in the control facilities 
received the infant’s take home dose in AnC. When 
analysed by whether or not the mother received the 
infant’s nevirapine dose to take home, infant’s uptake 
was	borderline	statistically	significant	(p=0.085).	Of	
those women who delivered at home, uptake was 
highest among those whose mothers received the 
dose to take home (93% vs. 53%, p=0.008). 
July 2010 East african MEdical Journal   289
table 2
Infant uptake of the nevirapine dose by study group and treatment population
 Infant took dose (%)  Infant did not   p-value & 
  take dose (%)  standard error1 
Study group 
   Intervention (n=85) 94  5 p-value = 0.096
   Control (n=75)  88  12 Se=0.0469 
Treatment population*
   Received dose to take-home (n=102)  95 5 p-value = 0.085 
   did not receive dose to take-home (n=58)  86  14 Se=0.0576 
Of clients who delivered at their 
home or at another person’s home 
   Received dose to take-home (n=45)  93  7 p-value = 0.008 
   did not receive dose to take-home (n=15) 53  47  Se=0.1646 
1The difference in the estimated proportions between intervention and control groups was tested using a 
generalized estimating equation (Gee) approach accounting for clustering. 
*Some mothers in control group were given the nVp syrup take home by providers 
 A recalculation of the inter-cluster (facility) 
correlation using the kappa statistic yielded a kappa 
of 0.019 which is greater than the rho of 0.002 that we 
used to estimate sample sizes. While the inter-cluster 
correlation found in this study is still quite low, our 
underestimate of it during sample size calculations 
may have slightly underestimated the needed sample 
size. nonetheless, the largest contributor to the lack 
of	statistical	significance	comes	from	the	fact	that	the	
differences between groups is smaller than what we 
estimated. 
	 Few	maternal	characteristics	were	significantly	
associated with uptake of the infant’s nevirapine 
dose. Infants who received their doses compared to 
those	who	did	not	were	significantly	more	likely	to	
be born to women who had four or more AnC visits 
(54% vs 14%, p=0.05) (results not shown). mothers’ 
age, education, employment, marital status, parity, 
and	place	of	delivery	were	not	significantly	associated	
with infant uptake. 
 despite random assignment, there were 
differences between intervention and control 
groups in terms of women’s reports of previous 
HIV testing and HIV status disclosure, factors 
which may affect uptake of nevirapine. Women in 
the intervention group were 66% less likely to have 
ever been tested for HIV prior to the intervention 
(Table 3). Of those who had ever been tested, the 
intervention group was also less likely (on the 
order of 38 percentage points) to know that they 
were HIV positive. 
 Women in the intervention group were also less 
likely to disclose their HIV status or to talk with their 
partners about nevirapine. They were much less likely 
compared to the control group to have disclosed 
their HIV status, to know their partners’ HIV status, 
to have talked with their partners about nevirapine, 
or to say that their partner strongly approved about 
using nevirapine (Table 3). 
 Almost all mothers reported taking their 
nevirapine dose, and almost all of those mothers took 
their dose within 24 hours of delivery. Similarly, all 
but one infant who got their dose received it within 
the	first	two	days	after	delivery	(Table	4).	Fifty	one	
percent of women in the intervention group reported 
giving the infants their dose compared to 17% in the 
control group. This was the case despite the majority 
of mothers delivering in health facilities where one 
would expect a provider to give the infant’s dose. 
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table 3
Women’s reports of HIV testing, status disclosure and partners’ feelings about nevirapine
 Intervention (%) Control (%)
 (n=85) (n=75)
ever tested for HIV prior to pregnancy 24 40
Of those tested prior to pregnancy    (n=20)    (n=30)   
    knew HIV + status    45    83   
disclosure about HIV status    (n=85)    (n=75)   
    no one    45    20   
    Husband/partner/boyfriend    39    65   
    mother/father or mother/father in-law    11  33   
    Brother/sister    13   17   
    friend    0    13   
    Other health care provider    0    16   
    Other*    3    4   
partner’s HIV status    (n=85)    (n=75)   
    HIV positive    18    35   
    HIV negative    5    11   
    don’t know    78    55   
Of women with partners    (n=75)   (n=66)   
   Woman talked with partner about nVp for baby 32  68   
Of those who have talked with their partner    (n=24)   (n=45)   
   partner’s approval about using nVp for infant       
   Strongly approve    54    87   
   Approve    29    11   
   disapprove    8    0   
   Strongly disapprove  8    2   
1”Other” category includes ‘religious person’ or ‘other family member” 
table 4
Characteristics of nevirapine dose administration
 Intervention  Control 
 n=85 (%) n=75 (%)
mother took her dose  93  95 
Of mothers who took dose   (n=79)    (n=71)   
   When before the infant was born did       
   mother take dose
   Within 2 hrs    39   38   
   Within 1 day (2-24hrs)    57    61   
   more than 1 day (25 or more hours)    4    1   
Of infants who got dose:1    (n=80)    (n=66)   
When after delivery did the infant get       
His/her dose       
   less than 1 day    81    83   
   1-2 days    16    17   
   3 days    1    0   
person who gave infant his/her dose1 
   mother  51  17 
   midwife/nurse/Birth Attendant  43  80 
   family member/friend/husband  5  3 
1One “don’t know” response for the intervention group is not shown 
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	 Providers	confirmed	that	prior	to	the	intervention	
a minority of providers, and more often in the control 
group than intervention, were informally repackaging 
the infant nevi rapine dose for take home (Table 5). Only 
two-thirds of intervention group providers reported 
distributing the take home dose during the study because 
they worked in other areas of pmTCT where distribution 
of nevirapine was not part of their responsibilities. 
table 5
Providers’ perspectives on the take-home nevirapine dose concept 
 Intervention (%)  Control group (%)
 group (n=41) (n=25)
perceived likelihood that a woman who receives a take-home 
dose of nVp will give it to her newborn according to instructions 
   Very likely  37 44
   Somewhat likely  39 44
   not very likely  7 4
   Very unlikely  15 4
   don’t know/no response  2 4
perceived likelihood that a woman who was given the take 
home dose will return to the facility for delivery compared to a 
woman who is not given the take-home dose 
   more likely  27 12
   less likely  29 64
   no difference  44 24
ease/feasibility of systematically distributing take-home infant 
nVp dose1
   Very easy/feasible  35 38
   Somewhat easy/somewhat feasible  12 42
   Somewhat challenging/not very feasible  39 17
   Very challenging/not at all feasible  16 4
prior to the intervention, frequency with which providers 
informally re-packaged the infants nVp dose to take home 
   Very often  2 20
   Somewhat often  2 8
   not very often  17 20
   never  78 52
proportion of providers who distributed take-home dose 
during the intervention  63 n/a
Reasons given for not distributing infant take-home dose, 
among those who have not distributed the nVp dose (in the 
intervention clinics)2 
   Work in other areas of pmTCT  47 n/a
   Have not been oriented to distribute take-home dose  33 n/a
   Have not had supplies to be able to distribute it 20 n/a
Other 
   Administer it at delivery  7 n/a
   did not have repackaging materials 7 n/a 
   expect mothers to deliver in hospital  7 n/a
Intervention group providers’ perceptions  n=26 
  Have time with women to counsel on the take home dose  46  n/a 
	 	 Have	 time	 to	 fill	 and	 package	 syringe	 	 92	 	 n/a	
  foil pouch is easy to use  100  n/a 
	 	 Supplies	 of	 syringes	 are	 sufficient	 to	 always	 provide	 dose	 	 58	 	 n/a	
	 	 Supplies	 of	 nevirapine	 are	 sufficient	 to	 always	 provide	 dose	 	 54	 	 n/a	
1for providers in the intervention group, this question asked about “the ease of having distributed the infant’s 
nVp dose”, while the control providers were asked about “how feasible” this practice would be
2multiple responses allowed 
*Of providers who have ever distributed the infant npV dose (n=26)
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 providers who had distributed the dose felt that 
the foil pouch was easy to use and that they had time 
to	fill	and	package	the	syringe.	A	majority	of	providers	
felt the supplies of syringes and nevirapine were 
always	sufficient	to	provide	the	dose.	However,	less	
than half felt they had time to counsel women on the 
take home dose. 
 A majority of providers in the intervention 
group (55%) felt that systematically distributing the 
take home dose was challenging (Table 5). providers 
attributed	 these	 difficulties	 to	 client	 factors,	which	
would affect any prophylactic regimen or method of 
administration, rather than factors related to service 
delivery or provider skills. They reported that clients 
were afraid of their partners’ responses or clients were 
in denial about their HIV status (results not shown). 
dIscussIon 
The take home dose may increase infant uptake 
especially among women who deliver at home. 
Concerns that offering the infant dose to take home 
would encourage mothers to deliver at home were 
unfounded. providers embraced the intervention; 
however, they felt that HIV stigma and fear faced 
by clients made systematically distributing the take 
home dose challenging. Combined with previous 
research (7,13), this study indicates that offering the 
infant nevirapine dose to take home will increase 
uptake. 
 despite randomization, we found that the 
intervention group was much less likely to have ever 
been tested for HIV, to have disclosed their status 
to anyone much less their partners, to know their 
partners HIV status, or to talk with their partners 
about nevirapine for the baby. We hypothesize that 
the relatively higher levels of HIV status disclosure 
and communication with partners in the control 
group partially explains why the control group’s 
uptake was similar to that for the intervention group. 
Although	more	information	is	needed	to	confirm	that	
assumption, other studies have found that compliance 
with a pmTCT regimen is positively associated with 
partner	notification	and	partner	willingness	to	have	
an HIV test (14) and negatively associated with HIV 
fear and stigma and reluctance to notify partners 
(15-17). 
 The relatively short interval between recruitment 
into the study and delivery may also partially explain 
the relatively high uptake of nevirapine in both groups. 
due to manufacturer requirements, our study’s 
inclusion criteria required that women be at least 32 
weeks gestation. Women who adhere to maternal 
nevirapine were more likely to have a shorter mean 
interval between HIV testing and delivery than women 
who did not adhere (18), and low nevirapine uptake 
has been attributed to a lag time between HIV testing 
and issue of nevirapine (19). 
 The results of this study have multiple 
applications.	First,	they	are	specifically	relevant	for	
contexts where single dose nevirapine is the only ARV 
option. despite the WHO guidelines, some settings 
still	do	not	have	the	capacity	to	deliver	more	efficacious	
regimens, some women will still attend AnC too late 
to	start	more	efficacious	regimens,	and	many	women	
do not deliver in health facilities. This may be more 
likely the case for rural areas where home deliveries 
are	more	common.	The	findings	of	this	study	can	also	
be extended to promoting the take home nevirapine 
dose to increase the feasibility and uptake of extended 
postnatal delivery of nevi rapine regimens for infants 
born to HIV-infected women. finally, other groups, 
such as unICef, have drawn on the experiences 
developing the packaging for the infant’s dose and 
aspects of testing in development of the mother-Baby 
pack, which contains all the ARVs and other drugs 
needed to prevent perinatal HIV transmission (20). 
Issues around packaging, information for mothers, 
and concerns about non-return of mothers and infants 
are as relevant as pmTCT programmes continue to 
evolve and improve. 
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